Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-04-29 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制评价报告' which translates to '2023 Annual Internal Control Evaluation Report' for Jinling Pharmaceutical Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2023. The content includes detailed descriptions of internal control scope, evaluation standards, defect classifications, and conclusions about the absence of major defects. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The document length is 4127 characters, which is relatively short but contains substantive evaluation content rather than just an announcement or certification. The nature of the report aligns with an Audit Report / Information (AR) category, as it deals with internal control evaluation and related audit-like assessments, not the full annual financial statements (10-K) or other categories. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-29 Chinese
金陵药业股份有限公司2024年第三次独立董事专门会议的审查意见
Board/Management Information Classification · 90% confidence The document is a formal opinion from independent directors regarding the company's 2023 related party transactions, referencing compliance with Chinese company law and securities regulations. It is a specialized meeting opinion rather than a full financial report or announcement of voting results. The document length is short (679 characters) and it contains an official review or opinion statement from independent directors, which aligns with a Board/Management Information filing rather than an Annual Report, Audit Report, or Voting Results. There is no indication of financial statements or earnings data, nor is it a proxy or AGM material. Therefore, the best fit is Board/Management Information (MANG).
2024-04-29 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '金陵药业股份有限公司2024 年第一季度报告' which translates to 'Jinling Pharmaceutical Co., Ltd. 2024 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on non-recurring gains and losses. The document explicitly states it is a quarterly report for the first quarter of 2024 and mentions that it is unaudited. The length of the document (12,383 characters) and the presence of comprehensive financial statements confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-29 Chinese
金陵药业股份有限公司董事会审计委员会对会计师事务所2023年度履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee regarding the audit work performed by the accounting firm Tianheng for the fiscal year 2023. It includes information about the appointment process, audit scope, communication with auditors, and the audit committee's evaluation of the auditor's independence and performance. The document references the 2023 annual report audit but does not itself contain the full annual report or financial statements. It is a standalone audit-related report focusing on the audit process and results, consistent with an Audit Report / Information filing rather than the full Annual Report (10-K). The document length is 2168 characters, which is relatively short but contains substantive audit information, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2023
2024-04-29 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It details the amounts invested, types of financial products, risk control measures, and impact on company operations. The document is relatively short (1939 characters) and focuses on reporting the progress and status of cash management activities rather than providing comprehensive financial statements or detailed financial analysis. It does not contain full financial results or detailed financial data typical of an Interim Report or Annual Report. It is also not a certification or a regulatory compliance filing. The content fits best with a Capital/Financing Update (CAP) as it updates on the company's use of raised funds and cash management activities.
2024-04-24 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It details the opening of special settlement accounts, the amounts and types of cash management products purchased, risk control measures, and the impact on company operations. The document is relatively short (1948 characters) and serves as an update on financing activities related to the use of raised funds, rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis but focuses on capital management and investment activities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-04-18 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.